Grifols, S.A. (GRFS)

Market Cap	1.70B -70.2%
Revenue (ttm)	8.83B +4.3%
Net Income	472.00M +156.1%
EPS	0.69 +156.5%
Shares Out	211.18M
PE Ratio	3.59
Forward PE	2.34
Dividend	$0.14 (1.77%)
Ex-Dividend Date	Aug 12, 2025

Volume	485,797
Open	7.96
Previous Close	7.81
Day's Range	7.94 - 8.10
52-Week Range	6.19 - 11.14
Beta	1.19
Analysts	Hold
Price Target	10.15 (+26.4%)
Earnings Date	Jul 28, 2022

About GRFS

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as wel...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• IPO Date: May 17, 2006
• Employees: 23,737
• Stock Exchange: NASDAQ
• Ticker Symbol: GRFS
• Website: https://www.grifols.com

Financial Performance

In 2025, Grifols's revenue was 7.52 billion, an increase of 4.33% compared to the previous year's 7.21 billion. Earnings were 402.00 million, an increase of 156.05%.

Financial numbers in EUR

Analyst Summary

According to 2 analysts, the average rating for GRFS stock is "Hold." The 12-month stock price target is $10.15, which is an increase of 26.40% from the latest price.

Price Target

$10.15

(26.40% upside)

Analyst Consensus: Hold